Redirecting the antigen-specificity of polyclonal regulatory T cells to optimize their therapeutic efficacy and safety

Project 28

Project leader:

Prof. Dr. rer. nat. Max Löhning

CharitéUniversitätsmedizin Berlin / Deutsches Rheuma-Forschungszentrum

CCM: Campus Charité Mitte

Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie

Postal address:

Charitéplatz 1

10117 Berlin

t: +49 30 28460 760

f: +49 30 28460 603



We have shown that stably differentiated, antigen-specific Th2 cells can suppress efficiently both CD8+ and CD4+ T cell responses, even under inflammatory conditions. In a mouse model of type 1 diabetes (T1D), adoptively transferred stable Th2 cells delayed the onset of and ameliorated the disease. We now will investigate the molecular mechanisms of this suppression of developing and established T cell responses by stable Th2 cells. We will develop a protocol for the generation of stable Th2 cells for adoptive T cell therapy of human patients. We expect stable Th2 cells to be superior to Tregs particularly in suppressing established chronic inflammatory diseases.

Research Database

For more details please use the Charité undefinedresearch database.